Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis Flamm, S. L., Wyles, D. L., Wang, S., Mutimer, D. J., Rockstroh, J. K., Horsmans, Y. J., Kwo, P. Y., Weiland, O., Villa, E., Heo, J., Gane, E. J., Ryder, S. D., Welzel, T. M., Ng, T., Lovell, S. S., Liu, R., Krishnan, P., Kopecky-Bromberg, S., Asatryan, A., Trinh, R., Mensa, F. J. WILEY. 2017: 35A–36A

View details for Web of Science ID 000412089800063